In the phase 2 RESCUE-ALS clinical trial (NCT04098406), individuals early amyotrophic lateral sclerosis (ALS) who were treated with nanocrystalline gold for 12 weeks had improvement in their Motor Unit Number Index (MUNIX) compared with placebo. In a prespecified subset of participants with limb-onset ALS, MUNIX number and forced vital capacity (FVC) improved after 12 weeks […]

HONOLULU — Researchers in Hawaii are involved in the development of a drug they hope will one day be available to treat Alzheimer’s Disease. The drug is now in clinical trial and patients don’t even have to leave their homes to participate. Millions of people in the U.S. are affected by Alzheimer’s, it’s currently the […]

The HEALEY ALS platform trial, the first study to test several therapy candidates for amyotrophic lateral sclerosis (ALS) simultaneously, has completed enrollment for at least two of its first three regimens. These include Clene Nanomedicine’s CNM-Au8 (NCT04414345) and Biohaven Pharmaceuticals’ verdiperstat (NCT04436510). The recruitment status for the other initial arm of the trial, UCB’s zilucoplan (NCT04436497), remains unclear, but all three regimens […]